Table 1

Baseline characteristics for patients with SIRI ≤0.84 versus SIRI >0.84 in primary and validation cohort

Clinical parameterPrimary cohortValidation cohort
SIRI ≤0.84 (106)SIRI>0.84 (179)χ2 P valuesSIRI ≤0.84 (81)SIRI >0.84 (132)χ2 P values
Sex
 Male691416.420.011501079.680.002
 Female37383125
Age
 <5040660.020.88433530.010.932
 ≥50661134879
 BMI
 ≤25711383.480.062561032.100.147
 >2535412529
T stage
 T123244.500.21211172.720.497
 T229452835
 T334642948
 T420461332
N stage
 N017241.200.75312173.370.338
 N129422428
 N246863765
 N31427822
AJCC stage
 I560.710.870544.380.224
 II17241215
 III52844464
 IV32652049
Chemotherapy
 No22350.060.80618290.000.966
 Yes8414463103
IMRT
 No611000.080.78231570.500.480
 Yes45795075
PLR
 ≤112544717.73<0.001433317.25<0.001
 >112521323899
NLR
 ≤1.85722072.31<0.001561088.96<0.001
 >1.853415925122
MLR
 ≤0.29865298.09<0.001653951.64<0.001
 >0.29201271693
  • AJCC, American Joint Committee on Cancer; BMI, body mass index; IMRT, intensity-modulated radiotherapy; MLR, monocyte lymphocyte ratio.; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; SIRI, Systemic Inflammation Response Index.